| Name | Title | Contact Details |
|---|---|---|
Kevin Lawler |
Senior Director Admin/Human Resources | Profile |
A cancer diagnosis is something no one wants to hear. Today, it is often detected late, once it has spread and treatment options are often limited. But cancer is curable if caught in the earlier stages. At Thrive Earlier Detection, our goal is to transform this outlook: to catch cancer earlier, when it can be more effectively treated. We are developing CancerSEEK, a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.
GenVault Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Diagenode is a leading global provider of complete solutions for epigenetics research, biological sample preparation, and diagnostics assays based in Liege, Belgium and NJ, USA. The company has developed a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company`s latest innovations include a unique, full automation system, the industry`s most validated antibodies, the Megaruptor shearing system for long fragment generation in sequencing, and epigenetics assay services.